Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday, Zacks.com reports. The firm currently has a $0.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 16.39% from the stock’s current price.
According to Zacks, “Zomedica Pharmaceuticals Corp. is a veterinary pharmaceutical and health care solutions company. It provides products for companion animals by focusing on the unmet needs of clinical veterinarians. The company’s portfolio includes diagnostics, devices, innovative drugs and drug-delivery technologies. Zomedica Pharmaceuticals Corp. is based in Ann Arbor, Michigan. “
NYSE:ZOM traded down $0.01 on Friday, reaching $0.21. The company’s stock had a trading volume of 14,029,415 shares, compared to its average volume of 45,431,780. Zomedica Pharmaceuticals Corp has a 1-year low of $0.11 and a 1-year high of $0.50. The firm has a market cap of $24.09 million, a PE ratio of -2.15 and a beta of 0.09. The business’s 50-day moving average price is $0.18 and its two-hundred day moving average price is $0.25.
An institutional investor recently raised its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock. Cambridge Investment Research Advisors Inc. lifted its position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) by 1.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,254,080 shares of the company’s stock after buying an additional 181,000 shares during the period. Cambridge Investment Research Advisors Inc. owned about 11.34% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) worth $2,325,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.87% of the company’s stock.
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.
Featured Story: Front-End Load
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.